SPINEWAY       EO 4,- Logo
FR001400N2P2
A400E3
ALSPW.PA

SPINEWAY EO 4,-

Loading quotes...

Forecast

There is no analyst data available for this company.

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, SPINEWAY EO 4,- had revenue of €5.73M and net profit of -€1.54M
(EUR) June 2026
YoY
Revenue 5.73M -
Gross profit 973K -
Net profit -1.54M -
EBITDA -1.24M -

Fundamentals

Metric Value
Market capitalization
€3.09M
Number of shares
35.54M
52-week high/low
€0.21 - €0.087
Dividends No
Beta
0.30
P/E ratio
-1.31
PEG ratio
-0.02
P/B ratio
0.13
P/S ratio
0.25

Company profile

Spineway SA engages in the design, manufacture, and marketing of implants and surgical instruments for treating disorder of spinal column. The company offers ayers rock, an anterior cervical interbody fusion cage; blue mountain, an anterior cervical interbody fusion plate; mont blanc, a posterior thoracolumbar pedicle screws; mont blanc baby, a pediatric growing rod system; mont blanc 3d+, a coplanar alignment system; kili, an anterior lumbar interbody fusion cage; twin peaks plif bullet shaped posterior lumbar interbody fusion cages; twin peaks olif graft vascularization interbody fusion cages; twin peaks tlif transforaminal lumbar interbody fusion cages; and mont blanc mis, a mini-invasive thoracolumbar system. It also provides sonora, a biomaterial for bone regeneration. In addition, the company exports its products. Spineway SA was incorporated in 2005 and is headquartered in Ecully, France.

Name
SPINEWAY EO 4,-
CEO
Stéphane Le Roux
Headquarters Ecully, ar
France
Website
IPO
02/13/2013
Employees 43

Ticker symbols

Exchange Symbol
Euronext
ALSPW.PA
Frankfurt
37S.F
Paris
ALSPW.PA
München
37S.MU
🍪

Parqet  uses cookies. Learn more